（精）杰诺维DPP-4抑制剂的同与异.ppt

下载文档 降价啦

43
0
约1.94万字
约 26页
2017-01-06 发布于湖北
举报
版权申诉
保障服务

（精）杰诺维DPP-4抑制剂的同与异.ppt

1、本文档共26页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV events defined as death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke and arrhythmias (including atrial fibrillation, supraventricular tachycardia, or palpitations), and heart failure. * We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV events defined as death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke and arrhythmias (including atrial fibrillation, supraventricular tachycardia, or palpitations), and heart failure. * 结果显示，捷诺维总体安全性良好，与非暴露组相比无差异。由于捷诺维是葡萄糖依赖性的降糖机制，低血糖发生率与非暴露组相比更低。对体重的影响也是中性。 2007年，捷诺维荣获了有“医药界诺贝尔奖”之称的Prix Galien （艾伦奖)最佳药物奖 Prix Galien奖是用于表彰可实质改善治疗效果，带给患者利益的创新药物的荣誉奖项，激励那些药学领域著名的研究成果 * * 捷诺维超过95个国家和地区上市，一年超过3300万张处方。 2011年成为全球第一大口服品牌降糖药。 * 维格列汀对DPP-4酶的抑制作用 0 20 40 60 80 100 0 4 8 12 16 20 24 第1天安慰剂维格列汀 50 mg qd 维格列汀 100 mg qd 对DPP-4 的抑制, %b C. F. Deacon, Obesity and Metabolism 13: 7–18, 2011 内部交流材料沙格列汀对DPP-4酶的抑制作用 Tahrani AA et al. Adv Ther. 2009;26(3):249–262.